GB2359562A - T cell immunoactivity potentiators containing shiit ake mushroom hypha extract - Google Patents
T cell immunoactivity potentiators containing shiit ake mushroom hypha extract Download PDFInfo
- Publication number
- GB2359562A GB2359562A GB0113001A GB0113001A GB2359562A GB 2359562 A GB2359562 A GB 2359562A GB 0113001 A GB0113001 A GB 0113001A GB 0113001 A GB0113001 A GB 0113001A GB 2359562 A GB2359562 A GB 2359562A
- Authority
- GB
- United Kingdom
- Prior art keywords
- cell activity
- cells
- extract
- lentinus edodes
- activity enhancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000000599 Lentinula edodes Species 0.000 title claims abstract description 54
- 235000001715 Lentinula edodes Nutrition 0.000 title claims description 51
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract description 5
- 230000000694 effects Effects 0.000 claims abstract description 58
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 22
- 239000003623 enhancer Substances 0.000 claims description 41
- 208000035143 Bacterial infection Diseases 0.000 claims description 14
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 14
- 230000009385 viral infection Effects 0.000 claims description 13
- 208000036142 Viral infection Diseases 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000003612 virological effect Effects 0.000 abstract description 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 92
- 210000005259 peripheral blood Anatomy 0.000 description 14
- 239000011886 peripheral blood Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 108091008874 T cell receptors Proteins 0.000 description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 6
- 230000000091 immunopotentiator Effects 0.000 description 6
- 241000609240 Ambelania acida Species 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000010905 bagasse Substances 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 108010059892 Cellulase Proteins 0.000 description 2
- 241000186779 Listeria monocytogenes Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 101100290380 Caenorhabditis elegans cel-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 101150044453 Y gene Proteins 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000016350 chronic hepatitis B virus infection Diseases 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Botany (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fodder In General (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
qw T cell activitiy potentiators and immunoactivity agents containing a shiitake mushroom hypha extract which are to be used in treating tumor or treating and/or preventing bacterial or viral infectious diseases by taking advantage of the effect of the shiitake mushroom hypha extract of remarkably potentiating the activity of qw T cells.
Description
2359562 SPECIFICATION y6T CELL IMMUNOACTIVITY ENHANCERS CONTAINING EXTRACT
OF LENTINUS EDODES MYCELIUM
FIELD OF THE INVENTION
The present invention relates to the development and preparation of y6T cell activity enhancers and therefore mmunopotent ators containing an extract of Lent nus edodes mycelium.
The present invention also relates to the development and preparation of foods, drinks and feeds containing an extract of Lentinus edodes mycel um and having a y6T cell act vlty-enhancing effect and therefore an mmunopotentiat ng effect.
The present invention also relates to the development and preparation of ant tumor agents, therapeutic agents against bacterial infections and therapeutic agents against viral infections containing an extract of Lentinus edodes mycel um.
PRIOR ART Characteristics of y6T cel 1 s
Peripheral T cells in animal blood are mainly classified into two groups based on the type of their cell surface antigens referred to as T cell receptors (TCR).
One type is an ccpT cell bearing TCR a and P chains on their cell surf aces, and the other is a y6T cell bearing TCR y and 8 chains. y6T cells are cytotoxic killer cells present at a level of only a few to about 10% in normal peripheral blood and lymphoid tissue in humans, and the characteristics of which are quite distinct from those of apT cells.
In humans, y6T cells are present in the intestinal tract, skin and peripheral blood or the like and elicit a local immunity. So f ar, y6T cells have been reported to have functions such as cytotoxicity against cancer cells, and protective activity against bacterial or virus infections, etc.
Phylaxis activity of 6T cells Some y6T cells in the spleen and other organs produce cytokines such as IL-4 or IFN-a in response to infection. It has been shown under experimental conditions that when these cells are lacking, resistance to bacterial infections is reduced. For example, there is one report which describes that resistance to Mycobacterium tuberculosis infection decreased in mice treated with a yb-type TCR antibody to transiently inhibit functions of y6T cells or mice deficient in the TCR y gene (Ladel C. et al., Eur. J 20 Immunol., 1995. 25:2877-2881). Another report describes that y5T cells appear during the early stage of infection with Listeria monocytogenes (Hiromatsu K. et al., J. Exp. Med -, 19 9 2, 17 5: 4 9 - 5 6). These f indings suggest that y6T cells play an important role in protecting against bacterial infections. It has also been reported that chronic hepatitis B virus infection induces the growth of y6T cells in the liver and spleen (Ozaki S. et al., J. Med. Invest., 1998, 44:215-217); and that vaccinia virus markedly increases during the early stage of infection in y6T cell-deficient mice as compared with normal mice (Welsh RM, et al., Immunol. Rev., 1997, 159:79-93). These findings suggest that y6T cells act not only on bacterial infections but also on viral infections.
Cytotoxicity of 6T cells against cancer cells y6T cells are a class of T cells that are capable of specifically targeting and killing autologous cancer cells, but show no cytotoxicity to autologous normal lymphocytes (such as apT cells). In this respect, in cancer therapy which employs activated y8T cells there is very little danger of side effects. In contrast to y6T cells, apT cells are known to kill autologous leukocytes rather than autologous cancer cells, and thus in cancer therapy which employs activated apT cells there is a likelihood that serious side effects will occur. In view of this, cancer therapy which employs activated y6T cells is desirable.
Moreover, y6T cells have similar characteristics to NK cells such as their MHC-nonrestricted cytotoxicity against cancer cells. y8T cells are present in peripheral blood of children at about 10% but decrease with age. This suggests that the increase in the occurrence of cancer with age may be related to a decrease in y6T cells. In peripheral blood of chicken, sheep, cow or the like, y6T cells are found at levels as high as 15-50%. The low incidence of tumors in these animals suggests that the 1 1 presence of peripheral y6T cells may contribute greatly to the inhibition of cancer. Pharmacoloaical effects of Lentinus edodes Lentinus edodes (Shiitake) is a common edible mushroom found in both Japan and China, and has been cultivated in Japan for around 300 years. The part of the mushroom used as food econsists of the reproductive body, also referred to as the fruiting body of fungi, which produces sporesfor reproduction, while the vegetative body includes hyphae which produce mycelia extending into a growing area such soil or logs.
Lentinus edodes has long been believed to have some effect against a variety of diseases and symptoms, but it is only relatively recently that any pharmacological effect has been elucidated. Various effects of extract of Lentinus edodes mycelium are reported, these include the inhibition of oncogenesis in the large bowel and liver and the growth of transplanted tumor cells and increased survival of animals in carcinogenesis experiments in rats and mice (N. Sugano et al., Cancer Letter, 27:1, 1985; Y.
Suzuki et al., Journal of the Japan Society of Coloproctology, 43:178, 1990, etc.); mitogenic activity (T.
Tabata et al., Immunopharmacology, 24:57, 1992; Y. Hibino et al., Immunopharmacology, 28:77, 1994, etc.); enhanced antibody production and inhibitory effects against immunological hepatocyte damage caused by ADCC (antibodydependent cell-mediated cytotoxicity) (Y. Mizoguchi et al., Journal of Hepato-Biliary-Pancreatic Study, 15:127, 1987).
These findings have acted as a catalyst for concentrated research into the pharmacological effects of ingredients of Lentinus edodes in the medical and pharmaceutical field. As a result, researchers have discovered that some of the constituents of Lentinus edodes can be used in the treatment of cancer or other diseases by restoring immune function in humans, and further that such constituents may also inhibit the onset of cancer.
In accomplishing the present invention the inventors have aimed to further elucidate pharmacological effects of an extract of Lentinus edodes mycellum, and also to search for new applications of the extract in the form of drugs, foods, drinks, feeds, etc. One object of the present invention is to develop and provide a y6T cell activity enhancer and therefore an immunopotentiator such as an antitumor agent, therapeutic agent against bacterial infections and therapeutic agent against viral infections containing an extract of Lentinus edodes mycelium. 20 Another object of the present invention is to use a y6T cell activity enhancer containing an extract of Lentinus edodes mycelium or an immunopotentiator containing an extract of Lentinus edodes mycelium to treat a tumor in a subject.
DISCLOSURE OF THE INVENTIO
As a result of intensive studies aimed at solving the above problems, the present invention has been accomplished - 5 t on the basis of the finding that an extract of Lentinus edodes mycelium. exhibits an effect of remarkably enhancing the activity of y6T cells.
Accordingly, the present invention has been developed and provided y6T cell activity enhancers and therefore immunopotentiators such as antitumor agents or therapeutic agents against bacterial or viral infections containing the extract of Lentinus edodes mycelium.
The present invention also provides methods developed for treating tumor, bacterial infections and viral infections using the extract of Lentinus edodes mycelium.
y6T cell activity enhancers or immunopotentiators of the present invention may be in the form of a pharmaceutical composition containing the extract of Lentinus edodes mycelium. and optionally a pharmaceutically acceptable carrier.
y6T cell activity enhancers or immunopotentiators of the present invention may be administered in the form of injection or oral, mucosal, gastrointestinal or percutaneous formulation.
y6T cell activity enhancers or immunopotentiators of the present invention may also be in the form of a food, drink or feed.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows that the proportion of y6T cells in peripheral blood increases following administration of the extract of Lentinus edodes mycelium of the present - 6 - D invention.
FIG. 2 shows the results of flow cytometric analysis of y5T cells before and after administration of the extract of Lentinus edodes mycellum.
FIG. 3 shows that the proportion of apT cells in peripheral blood decreases following administration of the extract of Lentinus edodes mycelium of the present invention.
THE MOST PREFERRED EMBODIMENTS OF THE INVENTIO An extract of Lentinus edodes mycelium used for enhancing the activity of y6T cells according to the present invention refers to an extract obtained by crushing and decomposing mycelia grown from Lentinus edodes cultured on a solid medium, or a solid medium itself containing Lentinus edodes mycelia in the presence of water and an enzyme.
An extract of Lentinus edodes mycelium used herein is preferably obtained by, but not limited to, the following process. Lentinus edodes spawn is inoculated on a solid medium based on bagasse (sugar cane residue) and defatted rice bran to grow mycelia, and then the solid medium containing the grown mycelia is delignified so that 30% by weight or less is able to pass through a 12-mesh sieve. To this delignified solid medium are added water and one or more enzymes selected from cellulase, protease or glucosidase while maintaining said solid medium at a temperature of 30-550C, and said solid medium is crushed 11 and ground in the presence of said enzyme so that at least 70% by weight of bagasse fiber is able to pass through a 12-mesh sieve. Then, the temperature is raised to 950C to ensure inactivation of the enzyme and sterilization, and the resulting suspension is filtered to give an extract of Lentinus edodes mycelium. The extract of Lentinus edodes mycelium as prepared above may be directly used in y6T cell activity enhancers of the present invention, but conveniently concentrated and freeze-dried into powder to be stored and used in various forms. The freeze-dried product is a brown powder with hygroscopic characteristics and has a peculiar taste and odor.
The extract of Lentinus edodes mycelium was tested for its in vivo y6T cell activity- enhancing effect by the method described in the examples below, and it will be seen from these examples that it has a remarkable in vivo 6T cell activity-enhancing effect.
y6T cell activity enhancers of the present invention are effective for treating and/or preventing tumor induced by tumor cells to which y6T cells are cytotoxic. 6T cell activity enhancers of the present invention are characterized in that they enhance the activity of y6T cells and thereby lead to the destruction of tumor cells under the action of the activated y6T cells, rather than having a direct action on specific tumor cells.
Consequently, tumor cells to be treated with y6T cell activity enhancers of the present invention may be not only malignant tumor cells but also benign tumor cells. and are 1 not limited to specific tumor cells. In addition, y6T cell activity enhancers containing the extract of Lentinus edodes mycelium and optionally a pharmaceutically acceptable carrier can be used in the form of both therapeutic and prophylactic compositions.
y6T cell activity enhancers of the present invention can also be used as therapeutic and/or prophylactic compositions for bacterial or viral infections. y6T cell activity enhancers of the present invention are intended to enhance the activity of y6T cells and thereby to remove infecting bacteria or viruses from the patient rather than to directly act on specific bacteria or viruses. Bacterial or viral diseases that can be treated with y6T cell activity enhancers of the present invention include such diseases as, but are not limited to, those caused by Mycobacterium spp. Listeria monocytogenes, hepatitis viruses (types A, B and C), human immunodeficiency virus, vaccinia virus and the like.
y6T cell activity enhancers of the present invention in the form of a therapeutic and/or prophylactic composition are administered most preferably via the oral route, but may also be administered via intravenous, intraperitoneal, subcutaneous, intramuscular, nasal, percutaneous or other route. Dosage forms suitable for oral administration include, but are not limited to, tablets, capsules, powders, granules, solutions, syrups, etc. Dosage forms suitable for nasal or percutaneous administration include, but not limited to, cataplasms, 9 M NJ -1 -i en 0 Ln (-n m 0) ld p 0 rt 0 U) cr m (n P) m l j 110 rt 0 h j 0 r G 0 h 0 rt 0 (D H. 0 md 0 H. 0 0) (D m 0 0 (D 0 B (D U) P. 0 P) rt h rt 0 m rt rt M (D H. r 0 0 0 0 (Q:Y m U) r 5 H. 0 (D - 0 (D y 0 10 h cr:Y r+ rt rt 0 0 li G 0 H. rt 0 0 0 C: C H. rt P) Y 0 0 (D - j i. rt H. (D rt H 0 rt k-3 h 0 0 m - h p 0 lTd (D E1 bd bl m r ke, h H. 0 0 0 rt H y 0 H. (0 H. r rt P. (D 0 0 03 N (D U) H Y (D P. rt H. H P) N h rt P) 0 H P P) r_; H j 0 0 rt (D P) (D (D 0 H. g 0 r m rt gi rt 0 U) (D H. H (D (D 0 (D (D (D 0 (D P) (D o P) o 0 rt H. P. P) j cr l 0 - 0 H. P) H 0 X p. Q r rt P) rt j (Q rt (D rt m F- 0 (D 0 0 M (D p) 0 (D H. H. (D H. (D H. bi. Vii U) (n H (D P) 0 U) F-J H. h (D C: r_:
0 (n 0 0 lz l 0 rt (D H 10 rt rt rt.:i m h 0 p) rt - 0 H. H.
h (D rt m cr 0 rt tn (D H. 0 H (D P) (D H. C), L r z H. P) e 0 0 (D 0 p) P) tn H. 0 rt H. M b_a H (n rt j U) 0 0 m rt -i 0 m rt F--i 3 P) H. M (D::r H. 5 0 0 P) (D (D H a H. p) H 0:3, (D N (a 0 m h C>,.,A H. 0 C ::I ft (D (D m P) (D:31 cr m (D.9::J P3 H (0 (D rt H H. U) H h 03 (0 0 H. cr 0 m P) 4 j (D P) ty, P) 03 (D H (D H. (Q (D 0 H. 0 (D (D 0 rt H r+ PC 0 (n 0 y j p) (D Y 0 0 pi rt (D (D r rt r-t (D to (D pi 10 0 0 0 rt 0 (D P 0 p. p) rt fl tn H. rt H. rt (D 0 (n 0 H U) P) rt ld 03 cr r+ 0 ld < rt CO p) H.
rt (D p) j (D 0 h- 0 M p) (D (D H H.
C rt:1 0 P) 0 H r, 0 o 0:j (D rt. rt P H M M (D P. 0 rt rt rt H. m H. H. 0 rt H P 01 0 H. H. 0 H. M 0 rt 0 0 H 0 U) 0 rt P) 01 0 p) :i tj, p C: 0 p 0 0 4 m rt t 0 rt rt 0 H h F- (D m - H.
k (D h m 0 0 (n P3 rt p) 0 H.
h f-h H m rt tn U) (D (0 (0 0 (D j bi U) (D (D m p rt 0 0 (D P) tn P):3 (D m (D rt H. (D U) 0 p) j H. P) M H::I 0:J, P h ll h rt m m rt C: 0 C) rt (D rt (D M U) rt U) 0 < 0 H. 0 h l rt (D U) m H.
(D (D 03 0 p) 1.3 r 0 0 rt h 0 h rt rt rt (D H. (D H. P. 0) C (D (D rt U) 0 H P) (0 0 rt 0 (Q (0 0 Li. X (D 0 H. >1 h (D 0 b (D 0 (D H. 0 (D:1 U) P3 F-i U) rt P) h 0 (D 0 l m n h 0 p ri- P) rt 0 (D rt (Q rt H. (D 0 rt P) P) rt P) l (D m li P) rt h H. h h cr 0 rt (D H- H. rt (0 r m 2 0 (D (D (D rt y (n rt:$ y (D rt (D y rt j (D 0 rt 0 0 U) r+ 1 1 traditionally ingested as a component of food. For example, the extract of Lentinus edodes mycelium is normally administered preferably at a dose of 100 mg - 10000 mg several times (about 2-3 times) daily (a total of 200 mg 300,00 mg daily), more preferably 500 mg - 5000 mg three times daily (a total of 1500 mg - 15000 mg daily), most preferably 1000 mg - 1500 mg three times daily (a total of 3000 mg - 4500 mg daily). It may be administered in combination with other antitumor agents.
y6T cell activity enhancers of the present invention can be provided in a dosage form also suitable for adoptive immunotherapy for treating tumor. Adoptive immunotherapy refers to a type of anti-tumor therapy intended to kill tumor cells by transferring into a subject sensitized cells, normally lymphocytes. In the case of the present invention, y6T cells are initially isolated from peripheral blood of the subject, and the isolated y6T cells are activated in vitro by a.y,6T cell activity enhancer of the present invention, and then the activated y6T cells are returned into the subject. As a result, tumor cells in the subject can be destroyed by the action of the activated y6T cells.
y6T cell activity enhancers of the present invention may be the extract of Lentinus edodes mycelium itself or pharmaceutical or veterinary compositions comprising a y6T cell activity enhancer containing the extract of Lentinus edodes mycelium and a pharmaceutically acceptable carrier.
y6T cell activity enhancers of the present invention can also be provided in the form of a food. Preferred forms of food include powders, granules, pastes, jellies, etc. Granules desirably are supplemented with sugars such as lactose to add a sweet taste. y6T cell activity enhancers of the present invention can also be provided in the form of a drink. These foods or drinks may be supplemented with vitamins, minerals such as calcium, alcohols, deodorants such as polyphenols in addition to the extract of Lentinus edodes mycelium. These foods or drinks include the categories of specific health foods, medical 10 foods or the like.
y6T cell activity enhancers of the present invention can also be provided in the form of a feed or feed additive. y6T cell activity enhancers of the present invention can be used as a feed or feed additive for domestic animals to treat and/or prevent tumor occurring in domestic animals or to treat and/or prevent bacterial or viral infections in domestic animals. As a result, the amount of therapeutic agents such as antibiotics currently used can be reduced, thereby reducing farming costs. Another advantage is that the period during which shipment of animals is suspended due to the administration of antibiotics can be shortened.
In vivo y6T cell activity- enhancing effect was tested in human subjects as follows. Human subjects initially received 3.6 9 of the extract of Lentinus edodes mycelium bulk powder daily for 7 days (a total of 25.2 g). Then, the proportion of y6T cells in peripheral blood after administration of the extract of Lentinus edodes mycelium was determined by flow cytometry as compared with the - 12 1 proportion before administration.
The following examples, which further illustrate the present invention, should not be taken as limiting the the scope of the invention thereto. Various changes and modifications can be made by those skilled in the art and such changes and modifications are also included in the scope of the present invention.
EXAMPLES
ExaMle 1: Preparation of an extract of Lentinus edodes myceliu A solid medium consisting of 90 parts by weight of bagasse and 10 parts by weight of rice bran was soaked with an appropriate amount of pure water, and then inoculated with Lentinus edodes spawn and allowed to stand in an incubator at controlled temperature and humidity to grow mycelia. After mycelia spread over the solid medium, the bagasse base was delignified so that 24% by weight or less may pass through a 12-mesh sieve. To 1.0 kg of this delignified medium were added 3.5 L of pure water and 2.0 g of purified cellulase while maintaining the solid medium at 400C to prepare a mediumcontaining mixture.
Then, the medium-containing mixture was circulated by a variable speed gear pump, during which the solid medium was crushed and ground under the gears for about 200 minutes so that about 80% by weight of bagasse fiber may pass through a 12-mesh sieve. The medium-conta ning mixture was crushed and ground while the temperature of said mixture was gradually increased. Then, the mediumcontaining mixture was further heated to 900C and allowed to stand for 30 minutes. This heating to 900C ensured inactivation of the enzyme and sterilization. The resulting medium-containing mixture was filtered through a 60-mesh filter cloth to give an extract of Lentinus edodes mycelium, solution, which was concentrated and then freezedried into an extract of Lentinus edodes mycelium bulk powder.
The extract of Lentinus edodes mycelium as prepared above contained 25.3% (w/w) carbohydrates determined by the phenol- sulfuric acid method, 19.7% (w/w) proteins determined by the Lowry method and 2.6% (w/w) polyphenols determined by the Folin-Denis method using gallic acid as standard. The extract of Lentinus edodes mycellum further contains 8% crude fat, 22% crude ash and about 20% soluble nitrogen-free materials other than carbohydrates.
The extract of Lentinus edodes mycellum had a sugar composition (%) as follows: Xyl 15.2, Ara 8.2, Man 8.4, Gul 39.4, Gal 5.4, GleN 12.0, GluUA 11.3.
Example 2: In vivo 6T cell activity- enhancing test of the extract of Lentinus edodes myceliu Three human subjects (subjects A-C) received orally 3.6 g/day of the extract of Lentinus edodes mycelium bulk powder daily for 7 days (a total of 25.2 g). After the period of administration of the extract of Lentinus edodes mycelium, peripheral blood was collected from the human subjects. The proportion of y6T cells in peripheral blood collected after administration was determined by flow cytometry as compared with the proportion in peripheral blood collected before administration. The results are shown in Figs. 1 and 2.
In all of the three subjects, the proportion of y6T cells in peripheral blood increased by an average of 40% or more after administration of the extract of Lentinus edodes mycelium as compared with before administration.
Table 1: Increase of the proportion of y8T cells in peripheral blood after administration Subject A Subject B Subject C Mean SEM Increase 124.39% 146.15% 150.00% 140.18%.t7.97% Peripheral blood collected from the same subject before and after administration was tested for other markers than y8T cells. As a result, the extract of Lentinus edodes mycelium showed no proliferative activity on 4T cells and on average the proportion of apT cells decreased (Fig. 3).
INDUSTRIAL APPLICABILITY y6T cell activity enhancers containing the extract of Lentinus edodes mycelium of the present invention were found to actually activate y6T cells. Thus, y6T cell activity enhancers of the present invention can be used for preventing or treating tumor, bacterial infections and - 1 C viral infections because they have the effect of protecting living bodies against tumor, bacterial infections and viral infections by inducing cytotoxic activity against tumor cells, antibacterial activity and antiviral activity of y6T cells. Moreover, 6T cell activity enhancers of the present invention are suitable for wide industrial application because they can be used safely without side effects.
They can also be used in domestic animals with bacterial and/or viral infections to reduce the amount of therapeutic agents currently used such as antibiotics, thereby reducing costs for raising. They also have the advantage that the period during which shipment is suspended can be shortened because antibiotics are not used.
- 16 1
Claims (13)
1. A y6T cell activity enhancer containing an extract of Lentinus edodes mycelium.
2. A pharmaceutical or veterinary y6T cell activity enhancer comprising an extract of Lentinus edodes mycelium and a pharmaceutically acceptable carrier.
3. The y6T cell activity enhancer of claim 1 or 2 f or oral administration.
4. The y6T cell activity enhancer of claim 1 in the form of a food.
5. The y6T cell activity enhancer of claim 1 in the form of a drink.
6. The y8T cell activity enhancer of claim 1 in the. form of a feed.
7. The y6T cell activity enhancer of claim 1 or 2 for injection or percutaneous absorption.
8. The y6T cell activity enhancer of claim 1 f or in vitro activating y6T cells collected from a subject.
9. The y8T cell activity enhancer of any one of claims 1 to 8 used for treating tumor.
10. The y6T cell activity enhancer of any one of claims 1 to 8 used for preventing or treating a bacterial infection or a viral infection.
11. A method for treating a tumor of a subject by administering in vivo the y6T cell activity enhancer of claim 9.
12. A method for preventing or treating a bacterial infection or a viral infection in a subject by 17 - t administering in vivo the y6T cell activity enhancer of claim 10.
13. A use of an extract of Lentinus edodes mycelium for the preparation of a y6T cell activity enhancer.
18
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10337822A JP2000157203A (en) | 1998-11-27 | 1998-11-27 | Enhancer for immunological activity of gamma delta t cell containing extract from mycelium of lentinus edodes sing. |
| PCT/JP1999/006617 WO2000032213A1 (en) | 1998-11-27 | 1999-11-26 | ηδT CELL IMMUNOACTIVITY POTENTIATORS CONTAINING SHIITAKE MUSHROOM HYPHA EXTRACT |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB0113001D0 GB0113001D0 (en) | 2001-07-18 |
| GB2359562A true GB2359562A (en) | 2001-08-29 |
| GB2359562B GB2359562B (en) | 2004-04-28 |
Family
ID=18312295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB0113001A Expired - Fee Related GB2359562B (en) | 1998-11-27 | 1999-11-26 | gamma delta T cell immunoactivity enhancers containing extract of Lentinus edodes mycelium |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JP2000157203A (en) |
| KR (1) | KR20010089497A (en) |
| CN (1) | CN1171631C (en) |
| CA (1) | CA2352459A1 (en) |
| GB (1) | GB2359562B (en) |
| HK (2) | HK1040913A1 (en) |
| TW (1) | TWI245636B (en) |
| WO (1) | WO2000032213A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO20014256D0 (en) | 2001-09-03 | 2001-09-03 | Bjoern Kristiansen | Preparation of immunostimulatory compound |
| JP2006273835A (en) * | 2005-03-04 | 2006-10-12 | Michishi Tani | Therapeutic agent for malignant tumor and food or beverage containing the same |
| JP4681363B2 (en) * | 2005-03-04 | 2011-05-11 | 美智士 谷 | Malignant tumor therapeutic agent and food and drink containing the same |
| EP1896600A2 (en) | 2005-06-15 | 2008-03-12 | Medimush A/S | Anti-cancer combination treatment and kit-of-part |
| JP5756270B2 (en) * | 2010-09-29 | 2015-07-29 | 小林製薬株式会社 | Cancer peptide vaccine therapy effect improving agent |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995025745A1 (en) * | 1994-03-24 | 1995-09-28 | Gradimir Misevic | Fucose containing proteoglycan or acid glycan and their pharmace utical use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0751511B2 (en) * | 1982-03-15 | 1995-06-05 | 味の素株式会社 | Cancer therapeutic agent containing interleukin-2 |
| JP2002270532A (en) * | 2001-03-14 | 2002-09-20 | Tokyo Electron Ltd | Heating device and thermal treatment apparatus |
-
1998
- 1998-11-27 JP JP10337822A patent/JP2000157203A/en active Pending
-
1999
- 1999-11-26 CA CA002352459A patent/CA2352459A1/en not_active Abandoned
- 1999-11-26 CN CNB998151882A patent/CN1171631C/en not_active Expired - Fee Related
- 1999-11-26 WO PCT/JP1999/006617 patent/WO2000032213A1/en not_active Application Discontinuation
- 1999-11-26 KR KR1020017006474A patent/KR20010089497A/en not_active Application Discontinuation
- 1999-11-26 TW TW093100696A patent/TWI245636B/en not_active IP Right Cessation
- 1999-11-26 GB GB0113001A patent/GB2359562B/en not_active Expired - Fee Related
-
2002
- 2002-02-27 HK HK02101523.2A patent/HK1040913A1/en unknown
- 2002-06-08 HK HK02104332.7A patent/HK1042652B/en not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995025745A1 (en) * | 1994-03-24 | 1995-09-28 | Gradimir Misevic | Fucose containing proteoglycan or acid glycan and their pharmace utical use |
Non-Patent Citations (1)
| Title |
|---|
| Immunology Letters Vol. 32 (3) 1992. Griffioen A et.al. pages 265-272 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000032213A1 (en) | 2000-06-08 |
| HK1042652B (en) | 2005-03-18 |
| TWI245636B (en) | 2005-12-21 |
| JP2000157203A (en) | 2000-06-13 |
| GB0113001D0 (en) | 2001-07-18 |
| HK1042652A1 (en) | 2002-08-23 |
| TW200412989A (en) | 2004-08-01 |
| CA2352459A1 (en) | 2000-06-08 |
| KR20010089497A (en) | 2001-10-06 |
| HK1040913A1 (en) | 2002-06-28 |
| CN1332634A (en) | 2002-01-23 |
| GB2359562B (en) | 2004-04-28 |
| CN1171631C (en) | 2004-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101919770B1 (en) | Manufacturing Method of Functional Foods Utilized White Grub | |
| KR20070117629A (en) | Fermentation composition having immunomodulating effect | |
| JP5144112B2 (en) | Brain protectant | |
| GB2359562A (en) | T cell immunoactivity potentiators containing shiit ake mushroom hypha extract | |
| KR100814351B1 (en) | Physiologically Active Compositions of Basidiomycetes and Araliaaceae | |
| JP3502620B2 (en) | Composition having anti-hepatitis action | |
| JP4484267B2 (en) | Cancer immunostimulant and allergy immunosuppressant | |
| KR20060130856A (en) | Detoxification of lacquer and the use of detoxified lacquer extract | |
| US6585974B1 (en) | Preventives for hepatopathy | |
| WO1999053937A1 (en) | Immunopotentiators and antitumor agents | |
| JP4245291B2 (en) | Bioactive composition and method for producing the same | |
| JP2009024027A (en) | Physiologically active composition | |
| JP2002000229A (en) | Health food | |
| JP3010258B2 (en) | Anti-HIV agent | |
| KR102662439B1 (en) | A composition comprising Fomitopsis pinicola for preventing or treating diabetes mellitus | |
| JP4269547B2 (en) | Hypoglycemic agent and method for producing the same | |
| CN114540202B (en) | Preparation method of sparassis crispa dry powder, physiological function active agent and application thereof | |
| JPH0912466A (en) | Lipid absorption inhibitor / excretion enhancer and high fat food | |
| KR20010101065A (en) | Lak activity potentiator originating in shiitake mushroom hyphae extract and lak activity potentiating preparations containing the same | |
| KR20230006634A (en) | Ginger processed product manufacturing method, and ginger processed product | |
| JP2007277155A (en) | Composition having anti-fatigue action and/or composition having endurance enhancing action | |
| JPS63208533A (en) | Crude drug raw material having medicinal effect on aids | |
| JPH0725781A (en) | Pharmaceutical for health preservation | |
| CN107349224A (en) | Application of the blattaria in terms of body fat rate is reduced | |
| DE102006017950A1 (en) | Dietary supplement to strengthen the immune system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1040913 Country of ref document: HK |
|
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 20101126 |